PolyActiva
PolyActiva is a clinical-stage biopharmaceutical company developing novel drug delivery solutions to improve outcomes for patients with ocular conditions. Their lead asset, PA5108, is a biodegradable ocular implant delivering sustained latanoprost therapy to reduce intraocular pressure in glaucoma and ocular hypertension. The company's PREZIA™ drug delivery platform uses covalent bonding for precise, consistent, and customizable drug release.
Funding Round: Series C
Funding Amount: $25M
Date: 18-Jun-2025
Investors: Australian Sovereign Wealth Fund, Brandon Capital
Markets: Biotech, Pharmaceuticals, Ophthalmology
HQ: Melbourne, Australia
Founded: 2010
Website: https://www.polyactiva.com/
LinkedIn: https://www.linkedin.com/company/polyactiva
Crunchbase: https://www.crunchbase.com/organization/polyactiva
Leave a Comment
Comments
No comments yet.